Mammary Cell News Volume 7.02 | Jan 22 2015

Progesterone and Wnt4 Control Mammary Stem Cells via Myoepithelial Crosstalk
Researchers provide genetic evidence that canonical Wnt signaling in the myoepithelium required progesterone receptor and Wnt4, whereas the canonical Wnt signaling activities observed in the embryonic mammary bud and in the stroma around terminal end buds are independent of Wnt4. [EMBO J] Abstract | Graphical Abstract

Tumor-Derived Osteopontin Reprograms Normal Mammary Fibroblasts to Promote Inflammation and Tumor Growth in Breast Cancer
The authors show that mammary fibroblasts can be educated by breast cancer cells to become activated to a pro-inflammatory state that supports malignant progression. [Cancer Res] Abstract

Functionalized Nanoscale β-1,3-Glucan to Improve Her2⁺ Breast Cancer Therapy: In Vitro and In Vivo Study
Investigators fabricated a targeted delivery system for doxorubicin using β-1,3-glucan as a carrier and decorated by trastuzumab antibody having the status of targeting agent against Her2⁺ breast tumors. In vitro cell viability assay on two breast cancer cell lines demonstrated acceptable toxicity against tested cell lines. [J Control Release] Abstract | Graphical Abstract

The Malignant Phenotype in Breast Cancer Is Driven by eIF4A1-Mediated Changes in the Translational Landscape
Immunohistochemical analysis was performed on over 3000 breast tumors to investigate the relationship among expression of eukaryotic initiation factor (eIF)4A1, the helicase-modulating proteins eIF4B, eIF4E and programmed cell death 4 (PDCD4), and clinical outcome. Modulation of eIF4A1, eIF4B and PDCD4 expression in cultured MCF7 cells all restricted breast cancer cell growth and cycling. [Cell Death Dis] Full Article

Acquisition of Docetaxel Resistance in Breast Cancer Cells Reveals Upregulation of ABCB1 Expression as a Key Mediator of Resistance Accompanied by Discrete Upregulation of Other Specific Genes and Pathways
Investigators developed a cell-culture-based discovery platform for docetaxel resistance and thereby identified key molecular mechanisms and predictive molecular characteristics to docetaxel resistance. The cell lines were characterized regarding sensitivity to docetaxel and other chemotherapeutics and subjected to transcriptome-wide mRNA microarray profiling. [Tumor Biol] Abstract

Curcumin Inhibits LPA-Induced Invasion by Attenuating RhoA/ROCK/MMPs Pathway in MCF7 Breast Cancer Cells
RhoA/ROCK/MMP signaling was found to be one of the lysophosphatidic acid (LPA)-induced pathways, which may be involved in invasion of breast cancer. Scientists investigated whether this pathway was involved in curcumin’s effect against LPA-induced invasion. [Clin Exp Med] Abstract

The miR-15 Family Enhances the Radiosensitivity of Breast Cancer Cells by Targeting G₂ Checkpoints
Researchers investigated the effects of radiation on the miR-15 family and found a time-dependent change in the expression of miR-15a/15b/16 in breast cancer cells postirradiation, as well as an increase in miR-15 family-mediated sensitization of breast cancer cells to radiation. [Radiat Res] Abstract

Quercetin Inhibits Proliferation and Invasion Acts by Up-Regulating miR-146a in Human Breast Cancer Cells
To determine the role of quercetin treated on breast cancer, researchers investigated the effect of quercetin on cell proliferation in human breast cancer cell lines MCF-7 and MDA-MB-231 with/without transfection of miR-146a mimic or anti-miR-146a. [Mol Cell Biochem] Abstract

Disequilibrium of BMP2 Levels in the Breast Stem Cell Niche Launches Epithelial Transformation by Overamplifying BMPR1B Cell Response
Chronic exposure of immature human mammary epithelial cells to high BMP2 levels initiated transformation toward a luminal tumor-like phenotype, mediated by the receptor BMPR1B. Under physiological conditions, BMP2 controlled the maintenance and differentiation of early luminal progenitors, while BMP4 acted on stem cells/myoepithelial progenitors. [Stem Cell Reports] Full Article | Graphical Abstract

CLINICAL RESEARCH

Phase III Open-Label Randomized Study of Eribulin Mesylate versus Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer Previously Treated with an Anthracycline and a Taxane
Women with metastatic breast cancer who had received prior anthracycline- and taxane-based therapy were randomly assigned to receive eribulin or capecitabine as their first-, second-, or third-line chemotherapy for advanced/metastatic disease. [J Clin Oncol] Full Article | Press Release

Dose-Dense Nonpegylated Liposomal Doxorubicin and Docetaxel Combination in Breast Cancer: Dose-Finding Study
A dose-finding study was performed to determine maximum tolerated doses of nonpegylated liposomal doxorubicin and docetaxel as a dose-dense schedule, to maintain dose intensity, and to limit toxicity, particularly cardiac. [Oncologist] Abstract | Full Article

Molecular Mechanism and Clinical Impact of APOBEC3B-Catalyzed Mutagenesis in Breast Cancer
APOBEC3B may be a candidate for therapeutic targeting because inhibition of this non-essential enzyme is predicted to decrease tumor mutation rates and diminish the likelihood of undesirable mutation-dependent outcomes such as recurrence, metastasis, and the development of therapy resistant tumors. [Breast Cancer Res] Full Article

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Advaxis Announces FDA Acceptance of Its Investigational New Drug Application to Commence First-in-Human Clinical Trials of ADXS-HER2
Advaxis, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug application to conduct a Phase I clinical study of ADXS-HER2 for the treatment of patients with metastatic HER2 expressing solid tumors. [Advaxis, Inc.] Press Release

From our sponsor: Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the mammary cell community.

Postdoctoral Positions – Cancer Bioengineering and Cancer Biology (University of Minnesota)

Director of Research (Dr. Susan Love Research Foundation)

Postdoctoral Research Fellow – Post-Transcriptional Gene Regulation Governing Cancer Cell Behavior (Fred Hutchinson Cancer Research Center)

Principal Investigator – Human Cancer Genomics and Mouse Modeling (Lunenfeld-Tanenbaum Research Institute)

Lab Manager – Precision Cancer Medicine (Boston University)

Postdoctoral Position – Precision Cancer Medicine (Boston University)

Postdoctoral Fellow – Wnt Signaling in Development and Disease (Van Andel Research Institute)

Postdoctoral Position – Experimental Breast Cancer Therapy (University of Pennsylvania)

Postdoctoral Position – Breast Cancer Metastasis (Northwestern University)

Scientist – Mammary Cell Research (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Research Technologist – Media Development (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.